Abstract
Idiopathic unconjugated hyperbilirubinemia (Gilberts syndrome, GS) is a relatively common congenital hyperbilirubinemia occurring in 3-7% of the world population. It has been recognized as a benign familial condition in which hyperbilirubinemia occurs in the absence of structural liver disease or hemolysis, and the plasma concentration of conjugated bilirubin is normal. Recently, it was reported that uncojugated bilirubin had neurotoxicity in the developing nervous system. The ‘neurodevelopmental hypothesis’ of schizophrenia was proposes that a yet-unidentified event occurring in utero or early postnatal life. We have observed that patients suffering from schizophrenia frequently present an increased unconjugated bilirubin plasma concentration when admitted to the hospital. Therefore, we had notice the relation between unconjugated bilirubin and the etiology and vulnerability of schizophrenia. Our reported findings suggest that there are significant biological and clinical character differences between schizophrenic patients with GS and without GS. From the viewpoint of heterogeneity of schizophrenia, there may be poor outcome for the subtype of schizophrenia with GS.
Keywords: Schizophrenia, (Gilbert's Syndrome), Hyperbilirubinemia, liver disease, neurodevelopmental hypothesis, etiology, heterogeneity
Central Nervous System Agents in Medicinal Chemistry
Title: Schizophrenia and Idiopathic Unconjugated Hyperbilirubinemia (Gilberts Syndrome)
Volume: 8 Issue: 4
Author(s): Tsuyoshi Miyaoka, Rei Wake, Maiko Hayashida and Jun Horiguchi
Affiliation:
Keywords: Schizophrenia, (Gilbert's Syndrome), Hyperbilirubinemia, liver disease, neurodevelopmental hypothesis, etiology, heterogeneity
Abstract: Idiopathic unconjugated hyperbilirubinemia (Gilberts syndrome, GS) is a relatively common congenital hyperbilirubinemia occurring in 3-7% of the world population. It has been recognized as a benign familial condition in which hyperbilirubinemia occurs in the absence of structural liver disease or hemolysis, and the plasma concentration of conjugated bilirubin is normal. Recently, it was reported that uncojugated bilirubin had neurotoxicity in the developing nervous system. The ‘neurodevelopmental hypothesis’ of schizophrenia was proposes that a yet-unidentified event occurring in utero or early postnatal life. We have observed that patients suffering from schizophrenia frequently present an increased unconjugated bilirubin plasma concentration when admitted to the hospital. Therefore, we had notice the relation between unconjugated bilirubin and the etiology and vulnerability of schizophrenia. Our reported findings suggest that there are significant biological and clinical character differences between schizophrenic patients with GS and without GS. From the viewpoint of heterogeneity of schizophrenia, there may be poor outcome for the subtype of schizophrenia with GS.
Export Options
About this article
Cite this article as:
Miyaoka Tsuyoshi, Wake Rei, Hayashida Maiko and Horiguchi Jun, Schizophrenia and Idiopathic Unconjugated Hyperbilirubinemia (Gilberts Syndrome), Central Nervous System Agents in Medicinal Chemistry 2008; 8 (4) . https://dx.doi.org/10.2174/187152408786848111
DOI https://dx.doi.org/10.2174/187152408786848111 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and Biological Applications of Triazole Derivatives – A Review
Mini-Reviews in Organic Chemistry Effect of the NMDA-Receptor Antagonist Dextromethorphan in Infant Rat Pneumococcal Meningitis
Current Drug Metabolism MAP Kinase Pathways in Neuronal Cell Death
CNS & Neurological Disorders - Drug Targets Diabetes and Complications: Cellular Signaling Pathways, Current Understanding and Targeted Therapies
Current Drug Targets The Controversial Role of Adenosine A2A Receptor Antagonists as Neuro-protective Agents
Current Medicinal Chemistry - Central Nervous System Agents Update on Alzheimer’s Disease Therapeutics
Reviews on Recent Clinical Trials Is the Modulation of Autophagy the Future in the Treatment of Neurodegenerative Diseases?
Current Topics in Medicinal Chemistry Immune Therapy of Multiple Sclerosis - Future Strategies
Current Pharmaceutical Design Evaluation of Vancoplus Versus Ceftriaxone Against Cephalosporin Resistance MRSA Strain in Experimental Meningitis Model
Cardiovascular & Hematological Disorders-Drug Targets Omega-3 Polyunsaturated Fatty Acids and Depression: A Review of the Evidence
Current Pharmaceutical Design The Role of Cannabinoids in Inflammatory Modulation of Allergic Respiratory Disorders, Inflammatory Pain and Ischemic Stroke
Current Drug Targets Hypoxia Helps Glioma to Fight Therapy
Current Cancer Drug Targets The Rapidly Changing Composition of the Global Street Drug Supply and its Effects on High-risk Groups for COVID-19
Current Psychopharmacology Potential Therapeutic Strategies of Regenerative Medicine for Renal Failure
Current Stem Cell Research & Therapy Short-Term Intra-Nasal Erythropoietin Administration with Low Sialic Acid Content is without Toxicity or Erythropoietic Effects
Current Neurovascular Research The Offer of Chemistry to Targeted Therapy in Cancer
Recent Patents on Biotechnology Quercetin in Attenuation of Ischemic/Reperfusion Injury: A Review
Current Molecular Pharmacology Regulation of Apoptosis by Gram-Positive Bacteria: Mechanistic Diversity and Consequences for Immunity
Current Immunology Reviews (Discontinued) Healing Effects of Curcumin Nanoparticles in Deep Tissue Injury Mouse Model
Current Drug Delivery Participation of the Cannabinoid System in the Regulation of Emotional- Like Behaviour
Current Pharmaceutical Design